• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Adv . Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant

tetano

Editor, Senior Moderator
Sci Adv


. 2022 Jan 28;8(4):eabm0300.
doi: 10.1126/sciadv.abm0300. Epub 2022 Jan 28.
Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant


Wan Yang[SUP] 1 [/SUP], Sharon K Greene[SUP] 2 [/SUP], Eric R Peterson[SUP] 2 [/SUP], Wenhui Li[SUP] 3 [/SUP], Robert Mathes[SUP] 2 [/SUP], Laura Graf[SUP] 2 [/SUP], Ramona Lall[SUP] 2 [/SUP], Scott Hughes[SUP] 4 [/SUP], Jade Wang[SUP] 4 [/SUP], Anne Fine[SUP] 2 [/SUP]



Affiliations

Abstract

To characterize the epidemiological properties of the B.1.526 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) variant of interest, here we used nine epidemiological and population datasets and model-inference methods to reconstruct SARS-CoV-2 transmission dynamics in New York City, where B.1.526 emerged. We estimated that B.1.526 had a moderate increase (15 to 25%) in transmissibility, could escape immunity in 0 to 10% of previously infected individuals, and substantially increased the infection fatality risk (IFR) among adults 65 or older by >60% during November 2020 to April 2021, compared to estimates for preexisting variants. Overall, findings suggest that new variants like B.1.526 likely spread in the population weeks before detection and that partial immune escape (e.g., resistance to therapeutic antibodies) could offset prior medical advances and increase IFR. Early preparedness for and close monitoring of SARS-CoV-2 variants, their epidemiological characteristics, and disease severity are thus crucial to COVID-19 (coronavirus disease 2019) response.
 
Back
Top Bottom